Tanner Pharma Group Signs a Distribution Agreement for Partner Therapeutics’ Product, Leukine®

For Immediate Release

Lindsey Stevens
Tanner Pharma Group

CHARLOTTE, N.C.Tanner Pharma Group, a global provider of integrated specialty access solutions, has announced the signing of a distribution agreement with Partner Therapeutics, Inc. (PTx), an integrated biopharmaceutical company. The agreement names Tanner Pharma Group as a distributor of Leukine® (sargramostim) in areas outside of the United States and Canada where the product is not yet registered. Leukine® (sargramostim) is used to help increase the number and function of white blood cells after bone marrow transplantation.

The ex-US-and-Canadian distribution will be managed by TannerGAP, Inc. (“TannerGAP”), a wholly owned subsidiary of Tanner Pharma Group. TannerGAP offers turnkey global access solutions for the distribution of products from markets of supply to markets of demand.

Banks Bourne, Chairman and Founder of Tanner Pharma Group, commented, “We have customized a program for Partner Therapeutics through which we can fulfill healthcare provider requests for Leukine® (sargramostim) in countries outside the US and Canadian markets. TannerGAP is pleased to be working with Partner Therapeutics to expand the distribution of Leukine® (sargramostim) to patients in need around the world.”

Robert Mulroy, CEO of Partner Therapeutics, added, “We are pleased to be working with Tanner to support a named patient access program to help meet the significant demand for Leukine® outside of North America. Tanner has proven capabilities to support physicians and help patients worldwide gain access to critical medicines and we look forward to working in partnership to improve access and treatments.”

About Tanner Pharma Group

For over 15 years, Tanner Pharma Group has provided highly specialized pharmaceutical services to its partners. Companies partner with Tanner Pharma to license and commercialize their products in challenging international markets, develop and manage their Global Access Programs, and source comparator drugs for clinical trials and bioanalysis. For more information, visit www.tannerpharma.com.

About Partner Therapeutics (PTx)

PTx is an integrated commercial stage biotech company focused on the development and commercialization of therapeutics that improve health and economic outcomes in the treatment of cancer. PTx’s development focus spans the entire range of cancer therapy from primary treatments to supportive care. The company believes in delivering great products in support of medical teams with the purpose of creating the best possible outcomes for patients and their families. For more information, visit www.PartnerTx.com.


About Tanner Pharma Group

For over 15 years, Tanner’s executive team has provided specialty distribution of pharmaceuticals from markets of availability to markets of need. When healthcare providers in international markets require treatments not currently available in their home market, they rely on Tanner to source and deliver the product from its global network of pharmaceutical manufacturers. Based on its track record of accountability and experience managing regulatory-compliant access programs, top pharmaceutical and biotech companies partner with Tanner to develop and manage their global access programs. By partnering with Tanner, pharma and biotech companies are able to focus on their primary markets while ensuring that patients in international markets of need are receiving their products through a strictly controlled channel.

Tanner’s International Access Division serves providers in 24 of the most challenging countries by developing, implementing and managing global access programs including Named Patient Programs, Expanded Access Programs, Compassionate Use Programs, Government & Private Provider Tender fulfillment and Emergency Supply allocations. Tanner’s Clinical Trials Division procures comparator products for manufacturers, CRO’s and research centers from a broad range of sources. Additionally, the company is able to provide clinical trial logistics and inventory management for trials conducted in the U.S., Europe, Mexico and Brazil.

Headquartered in the U.S., Tanner’s reach includes Europe, Northeast Asia, Southeast Asia, the Middle East, Australia, Canada and Latin America, including Brazil, Mexico, the Caribbean, Central America and all of South America.

For more information about Tanner Pharma Group, please visit www.tannerpharma.com.

For more information about Merz or the Company’s products, please visit www.merzusa.com.

Contact Us